S&P 500   2,631.32 (-99.06%)
DOW   22,400.02 (+0.32%)
QQQ   193.26 (+0.64%)
AAPL   259.24 (+1.74%)
FB   169.30 (+2.02%)
MSFT   161.36 (+0.71%)
GOOGL   1,167.13 (+1.82%)
NVDA   268.65 (+1.15%)
BABA   195.96 (+2.45%)
MU   44.73 (+0.45%)
GE   8.06 (+2.15%)
TSLA   535.75 (+6.70%)
T   29.73 (-1.65%)
ACB   0.94 (+5.60%)
F   5.11 (+1.59%)
NFLX   378.72 (+2.09%)
BAC   22.24 (+0.91%)
GILD   75.20 (-0.96%)
DIS   101.26 (+1.46%)
S&P 500   2,631.32 (-99.06%)
DOW   22,400.02 (+0.32%)
QQQ   193.26 (+0.64%)
AAPL   259.24 (+1.74%)
FB   169.30 (+2.02%)
MSFT   161.36 (+0.71%)
GOOGL   1,167.13 (+1.82%)
NVDA   268.65 (+1.15%)
BABA   195.96 (+2.45%)
MU   44.73 (+0.45%)
GE   8.06 (+2.15%)
TSLA   535.75 (+6.70%)
T   29.73 (-1.65%)
ACB   0.94 (+5.60%)
F   5.11 (+1.59%)
NFLX   378.72 (+2.09%)
BAC   22.24 (+0.91%)
GILD   75.20 (-0.96%)
DIS   101.26 (+1.46%)
S&P 500   2,631.32 (-99.06%)
DOW   22,400.02 (+0.32%)
QQQ   193.26 (+0.64%)
AAPL   259.24 (+1.74%)
FB   169.30 (+2.02%)
MSFT   161.36 (+0.71%)
GOOGL   1,167.13 (+1.82%)
NVDA   268.65 (+1.15%)
BABA   195.96 (+2.45%)
MU   44.73 (+0.45%)
GE   8.06 (+2.15%)
TSLA   535.75 (+6.70%)
T   29.73 (-1.65%)
ACB   0.94 (+5.60%)
F   5.11 (+1.59%)
NFLX   378.72 (+2.09%)
BAC   22.24 (+0.91%)
GILD   75.20 (-0.96%)
DIS   101.26 (+1.46%)
S&P 500   2,631.32 (-99.06%)
DOW   22,400.02 (+0.32%)
QQQ   193.26 (+0.64%)
AAPL   259.24 (+1.74%)
FB   169.30 (+2.02%)
MSFT   161.36 (+0.71%)
GOOGL   1,167.13 (+1.82%)
NVDA   268.65 (+1.15%)
BABA   195.96 (+2.45%)
MU   44.73 (+0.45%)
GE   8.06 (+2.15%)
TSLA   535.75 (+6.70%)
T   29.73 (-1.65%)
ACB   0.94 (+5.60%)
F   5.11 (+1.59%)
NFLX   378.72 (+2.09%)
BAC   22.24 (+0.91%)
GILD   75.20 (-0.96%)
DIS   101.26 (+1.46%)
Log in

NASDAQ:BIIB - Biogen Stock Price, Forecast & News

$315.37
-0.76 (-0.24 %)
(As of 03/31/2020 11:55 AM ET)
Today's Range
$310.30
Now: $315.37
$319.94
50-Day Range
$268.88
MA: $312.97
$341.04
52-Week Range
$215.77
Now: $315.37
$374.99
Volume652,590 shs
Average Volume2.47 million shs
Market Capitalization$54.89 billion
P/E Ratio10.02
Dividend YieldN/A
Beta0.89
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More
Biogen logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.38 billion
Cash Flow$41.06 per share
Book Value$73.93 per share

Profitability

Net Income$5.89 billion

Miscellaneous

Employees7,400
Market Cap$54.89 billion
Next Earnings Date4/22/2020 (Estimated)
OptionableOptionable

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.


Biogen (NASDAQ:BIIB) Frequently Asked Questions

How has Biogen's stock been impacted by COVID-19 (Coronavirus)?

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BIIB shares have increased by 6.7% and is now trading at $314.06. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Biogen?

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 3 sell ratings, 16 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biogen.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, April 22nd 2020. View our earnings forecast for Biogen.

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) issued its quarterly earnings data on Thursday, January, 30th. The biotechnology company reported $8.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.02 by $0.32. The biotechnology company had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.51 billion. Biogen had a return on equity of 46.51% and a net margin of 40.96%. The firm's revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the company posted $6.99 EPS. View Biogen's earnings history.

How will Biogen's stock buyback program work?

Biogen announced that its board has approved a share buyback plan on Monday, December 23rd 2019, which authorizes the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided EPS guidance of $31.50-33.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $31.98. The company issued revenue guidance of ~$14.0-14.3 billion, compared to the consensus revenue estimate of $13.85 billion.

What price target have analysts set for BIIB?

30 analysts have issued 1 year target prices for Biogen's shares. Their forecasts range from $231.00 to $410.00. On average, they expect Biogen's stock price to reach $325.17 in the next twelve months. This suggests a possible upside of 3.5% from the stock's current price. View analysts' price targets for Biogen.

Has Biogen been receiving favorable news coverage?

Media headlines about BIIB stock have been trending very positive recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biogen earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutBiogen.

Are investors shorting Biogen?

Biogen saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 3,560,900 shares, an increase of 13.4% from the February 27th total of 3,140,000 shares. Based on an average trading volume of 1,835,900 shares, the days-to-cover ratio is presently 1.9 days. Approximately 2.1% of the shares of the company are short sold. View Biogen's Current Options Chain.

Who are some of Biogen's key competitors?

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Celgene (CELG), Walt Disney (DIS), Micron Technology (MU) and Boeing (BA).

Who are Biogen's key executives?

Biogen's management team includes the following people:
  • Mr. Michel Vounatsos, CEO & Director (Age 57)
  • Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 54)
  • Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 62)
  • Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 50)
  • Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 53)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $314.06.

How big of a company is Biogen?

Biogen has a market capitalization of $54.67 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe. View additional information about Biogen.

What is Biogen's official website?

The official website for Biogen is http://www.biogen.com/.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]


MarketBeat Community Rating for Biogen (NASDAQ BIIB)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,589 (Vote Outperform)
Underperform Votes:  1,020 (Vote Underperform)
Total Votes:  2,609
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: Dollar Cost Averaging

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel